About Event
The 3rd Targeted Radiopharmaceuticals Summit US 2024 – What’s It About?
While the radiopharmaceuticals field is riding a wave of investment and excitement following milestone acquisitions and approvals, getting here has been no mean feat. Building a radiopharmaceutical clinical and manufacturing workforce has been driven by collaboration across the industry and it certainly does not stop here.
Across three-days of unmatched content we will dive into challenges in bridging clinical workforce gaps, securing an ongoing radioisotope supply, overcoming external beam dose regulations and move toward new targets and novel personalized approaches.
The 3rd Annual Targeted Radiopharmaceutical Summit returns bigger and better than ever with the thought leaders who are spearheading the industry from Novartis, Bayer, Fusion Pharmaceuticals, Telix, AstraZeneca, Ratio Therapeutics and more.
Unmissable 2024 Highlights:
Discover next-generation targets and novel targeting approaches from LRRC15, pre-targeting, Auger emitters and dual-isotope approaches with UCLA, Weill Cornell and Ariceum
Hear groundbreaking clinical data from Novartis’ NETTER-2 first-line treatment for patients with advanced gastroenteropancreatic NET, Fusion’s antibody and small molecule programs and much more
Advance your isotope evaluation and quality control methods for radiopharmaceutical manufacturing, expand your robust isotope supply chain management and identify process optimization to address bottlenecks with Bayer, Telix and Washington University School of Medicine
Drive collaboration, address clinical silos and optimize nuclear medicine in the clinic by bringing together medical oncologists, radio pharmacists, nuclear medicine physicians, radiochemists, bioengineers and more who are working with patients every day
Unlock the potential of combination-based approaches to address target heterogeneity, radio-resistance and improve the therapeutic index with Weill Cornell, Fusion Pharma and Convergent Therapeutics